Paliperidone Palmitate 3-Month Formulation
Neurotransmitter Agents
Luye Pharma Group Ltd.Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Neurotransmitter Agents cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vts-K Theresa Jacob, PhD, MPH | Phase 4 | BB |
Guanfacine Maimonides Medical Center | Phase 4 | BB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Theresa Jacob, PhD, MPH | Phase 3 | B |
MIDAZOLAM Theresa Jacob, PhD, MPH | Phase 3 | B |
(2R,6R)-HYDROXYNORKETAMINE National Institute of Mental Health (NIMH) | Phase 2 | CCC |
ly03010 Luye Pharma Group Ltd. | Phase 1 | CCC |
LIDOCAINE Aretaieion University Hospital | N/A | D |
Same molecule, other indications
Paliperidone Palmitate 3-Month Formulation is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →